久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Provention Bio Initiates Trial Evaluating PRV-3279 in Lupus americanpharmaceuticalreview
    August 09, 2019
    Provention Bio has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase 1b/2a clinical trial evaluating PRV-3279. PRV-3279 is a humanized diabody (a bispecific scaffold biologic molecule) targeting the B-cell surface prote
  • First Subject Dosed In Phase 1 Trial Evaluating INP105 americanpharmaceuticalreview
    August 30, 2018
    Impel NeuroPharma announced the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-and-active controlled crossover study of their intranasal olanzapine product, INP105, dosed via Impel's proprietary Precision Olfactory Delivery,
PharmaSources Customer Service